Catálogo de publicaciones - libros

Multiple myeloma (MM) consists of a malignant proliferation of BM plasmatic cells (BMPCs), which produce a monoclonal protein that can be found in serum and/or urine, resulting in skeletal involvement, hypercalcemia, anemia, renal function impairment, and/or soft-tissue plasmacytomas. The cause is unknown.

Systemic light chain (AL) amyloidosis is a protein misfolding and deposition disorder with an incidence of 5–12 persons per million per year. Clonal plasma cells or rarely B cells produce immunoglobulin light chains with the potential to misfold.

POEMS syndrome (acronym of polyradiculoneuropathy, organomegaly, endocrinopathies, monoclonal protein, and dermopathy, skin) is a rare multisystemic disease due to an underlying plasma cell neoplasm.

First-line therapy for patients with advanced stage follicular lymphoma (FL) in need of treatment is to administer chemoimmunotherapy followed by maintenance rituximab (RTX).

CLL is a rare indication for HSCT since it usually follows an indolent course.

Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of morphologically medium to large B-lymphoid cells. The most recent WHO classification of tumors of hematopoietic and lymphoid tissues (Swerdlow et al.

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, which is characterized by the chromosomal translocation t(11;14)(q13;q32) and overexpression of cyclin D1 in the vast majority of cases.

BL accounts for around 2% of all adult NHL with a higher incidence in patients with immunodeficiency and in patients who are HIV positive.

HL is a malignancy arising from germinal centre or post-germinal centre B cells. The cancer cells form a minority of the tumour and are surrounded by a reactive inflammatory milieu comprising lymphocytes, eosinophils, neutrophils, histiocytes and plasma cells. These malignant cells can be pathognomonic, multinucleate giant cells or large mononuclear cells and, together, are referred to as Hodgkin and Reed-Sternberg (HRS) cells.

Primary immunodeficiency (PID) diseases arise from genetic defects that lead to abnormalities in immune cell development or function with a wide spectrum in severity and clinical manifestations.